Financial Results & Reports

ViroGates’ current and previous financial results, reports, analyst presentations, IPO documents, and more, are listed below.

DKK ('000) unless otherwise stated	H1, 2021	H1, 2020	% change	Q2, 2021	Q2, 2020	% change	2020
INCOME STATEMENT
Net revenue	3,891	1,205	223%	1,815	760	139%	5,353
EBIT (operating profit/loss)	-9,896	-10,995	-10%	-5,296	-4,562	16%	-19,729
Net profit/loss for the period	-9,321	-10,545	-12%	-5,046	-4,358	16%	-18,736
BALANCE SHEET
Assets	27,958	43,697	-36%	27,958	43,697	-36%	38,246
Equity	24,768	39,505	-37%	24,768	39,505	-37%	31,313
Liabilities	3,190	4,192	-24%	3,190	4,192	-24%	6,933
CASH FLOW STATEMENT
Cash flow from operating activities	-14,977	-9,812	53%	-5,014	-4,128	21%	-15,600
Cash flow from investing activities	0	0	-	0	0	-	-118
Cash flow from financing activities	2,775	7,835	-65%	2,775	7,835	-65%	7,835
Total cash flows	-12,201	-1,977	517%	-2,239	3,707	-160%	-7,883
OTHER KEY FIGURES AND RATIOS
Cash end-of-period	21,323	39,431	-46%	21,323	39,431	-46%	33,525
Average number of employees, ultimo period (no.)	14	14	-	14	14	-	14
Earnings per share before dilution (DKK/share)	-2.97	-3.47	-14%	-1.60	-1.43	12%	-6.08
Earnings per share after dilution (DKK/share)	-2.79	-3.04	-8%	-1.51	-1.26	20%	-5.51
Number of shares before dilution (#)	3,170,083	3,125,426	1%	3,170,083	3,125,426	1%	3,125,426
Number of shares after dilution (#)	3,373,356	3,342,117	1%	3,364,688	3,342,117	1%	3,320,923
Equity ratio (%)	89%	90%	-1%	89%	90%	-1%	82%

Annual Report 2020

In 2020, ViroGates made promising progress. Our team delivered revenue growth amidst the global COVID-19 pandemic and established a more robust platform for the future commercialization of our products. Despite challenges throughout the year, we demonstrated that our European strategy and commercial efforts are working.

Click here to download ViroGates’ Annual Report 2020.

Analyst Reports

2020

6 November 2020:Analyse af ViroGates A/S by Aktieinfo

27 October 2020:Market Focus Update by Västra Hamnen Corporate Finance

14 August 2020:Market Focus Update by Västra Hamnen Corporate Finance

30 March 2020: Market Focus Update by Västra Hamnen Corporate Finance

29 January 2020: Market Focus Initial Research by Västra Hamnen Corporate Finance

2019

12 April 2019: Analyse af ViroGates A/S by Aktieinfo

2018

4 October 2018: Analyse af ViroGates A/S by Aktieinfo

IPO 2018 Documents

ViroGates Prospectus 2018 (Full version in English)

ViroGates Prospectus 2018 (Summary in Swedish)

ViroGates Prospectus 2018 Announcement

ViroGates Brochure (in Swedish)

11 June 2018: Presentation at Aktiespararnas Småbolagsdag in Stockholm

12 June 2018: Presentation at InvestorDagen by the Danish Shareholders’ Association in Aarhus

Financial Results & Reports

Half-Year Report, H1 (Q2) 2021

Half-Year Report, H1 (Q2) 2021

Financial Results, H1 (Q2) 2021

Financial Results, H1 (Q2) 2021

Annual Report 2020

Annual Report 2020

Remuneration Report 2020

Previous Annual Reports

Previous Annual Reports

Previous Interim/Half-Year Reports

Previous Interim/Half-Year Reports

Analyst Reports

Analyst Reports

2020

2019

2018

IPO 2018 Documents

IPO 2018 Documents

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Quick Triage

TurbiLatex

ELISA Assay

Would you like to know more?

Thank you!

An error occured!

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

An error occured!

Webinar

Catch COVID-19